Micronized Cytisine Capsule Formulation for Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cytisine-based smoking cessation tablets face issues with mechanical stability, solubility, and compatibility in patients with galactose intolerance due to lactose presence, leading to instability and Maillard reactions, which affect cytisine stability and distribution.
Innovation Solution
A solid dosage form containing micronised cytisine (less than 10 µm in diameter) with corn starch, microcrystalline cellulose, colloidal silica, and magnesium stearate, formulated into a hard capsule without lactose, ensuring homogenous dispersion and stability through a process that avoids high temperatures and moisture, thereby preventing Maillard reactions and enhancing mechanical stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If lactose is used as an ancillary substance in cytisine tablets, then the tablet composition is formed, but Maillard reactions occur leading to cytisine degradation and brownish discoloration
Solution Approach 1:
The patent removes lactose from the tablet composition entirely, extracting the problematic substance that causes Maillard reactions. The formulation uses alternative excipients such as microcrystalline cellulose, corn starch, and pregelatinized starch that do not contain reducing sugars, thereby eliminating the chemical pathway for Maillard reaction while maintaining tablet manufacturability.
Solution Approach 2:
The patent introduces alternative excipients as intermediaries to replace lactose's functional roles in tablet formation. These substitutes provide necessary bulk, flow, and compression properties without the harmful chemical reactivity, acting as mediators that preserve manufacturing ease while protecting cytisine stability.
2Productivity
If high temperature is applied during tableting process, then the tabletting process is completed, but cytisine stability deteriorates due to thermal degradation
Solution Approach 1:
The patent modifies the temperature parameter of the tableting process to remain below 50°C, fundamentally changing the thermal conditions from conventional high-temperature compression to low-temperature processing. This parameter change preserves cytisine's thermal sensitivity while still achieving adequate tablet compression and binding through extended compression time or multiple passes.
Solution Approach 2:
The patent performs preliminary actions to prepare the tablet mixture in advance at low temperatures, including pre-mixing excipients and active ingredient, pre-compression, and using pregelatinized starch that has already undergone gelatinization before tableting. These preliminary steps reduce the need for high-temperature processing during the actual tableting operation.
3Reliability
If cytisine particle size is reduced to enhance solubility, then solubility improves, but mechanical resistance of tablet decreases
Solution Approach 1:
The patent creates a composite tablet structure where micronized cytisine (1-10 μm) is combined with multiple excipients having different physical properties. Microcrystalline cellulose provides structural framework, corn starch adds bulk and binding, and pregelatinized starch contributes to cohesion. This composite approach allows the use of highly divided cytisine for solubility while the excipient matrix provides mechanical strength.
Solution Approach 2:
The patent applies local quality by using micronized cytisine specifically in regions where solubility is critical (the dispersed active ingredient phase) while relying on the excipient matrix for overall structural integrity. The different components are distributed to perform their specific functions: ultra-fine cytisine for dissolution and the excipient blend for mechanical properties.
4Ease of manufacture
If complex physical processes are applied during tablet production, then the tablet is formed, but cytisine stability is compromised due to deleterious effects on the medicinal product
Solution Approach 1:
The patent extracts and eliminates complex physical processes from the manufacturing workflow, adopting a simplified direct compression approach. Conventional processes such as granulation, drying, and high-energy mixing are removed in favor of gentle, low-temperature mixing and compression that form tablets without subjecting cytisine to stressful physical conditions.
Solution Approach 2:
The patent employs a straightforward, single-step compression process that creates a tablet suitable for immediate use without requiring complex multi-stage processing. The formulation is designed to work in a single compression pass or minimal passes, eliminating the need for intermediate drying, re-wetting, or multiple compression cycles that would expose cytisine to repeated mechanical and thermal stress.
Data Source
AI summary
The subject of the present invention is solid dosage form containing cytisine and ancillary substances characterised in that it contains from 0.1% to 5% micronised cytisine, wherein all molecules have a diameter less than from 10 μπι, corn starch from 40% to 60%, preferably 99,9% particles sized from 5 μπι to 25 μπι, macrocrystalline cellulose in an amount from 40% to 60%, preferably the particle size is: 99% below 38μπι, wherein the mass ratio of ancillary substances to the active ingredient is from 1:19 to 1:999 and is in the form of a hard capsule as well as a method of obtaining it.